 RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohns U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035 - Opaganibs 475-patient global Phase 23 study in severe COVID-19 approaching completion with upcoming top-line results - Opaganib also undergoing two oncology Phase 2 U.S. studies as well as several development programs for inflammatory and viral indications, including Ebola - Continued expansion of patent estate protecting RHB-104 following positive Phase 3 study for Crohns disease; development path to approval being explored TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE August 23, 2021 RedHill Biopharma Ltd. NASDAQ:RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office USPTO has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029. 